Description: CC-90001 (CC90001; CC 90001) is a novel, potent and selective inhibitor of c-Jun N-terminal kinase (JNK) with potential anti-fibrotic activity. It inhibits JNK1/2 with IC50s of 11 and 31 nM, respectively. CC-90001 possesses low nanomolar JNK inhibitory potency, overall kinome selectivity, and the ability to inhibit cellular phosphorylation of the direct JNK substrate c-Jun. As for the physicochemical properties, CC-90001 also demonstrated excellent systemic exposure following oral dosing, enabling in vivo efficacy studies and the selection of CC-90001 for clinical development. CC-90001 is currently in clinical trials (Phase II) in patients with idiopathic pulmonary fibrosis (NCT03142191).

References:

[1] J Med Chem. 2021 Dec 13. doi: 10.1021/acs.jmedchem.1c01716. Online ahead of print.

[2] CC-90001, a Second Generation Jun N-Terminal Kinase (JNK) Inhibitor for the Treatment of Idiopathic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine 2017; 195:A5409.

Related CAS #: 1403859-14-2 (free base) 1946833-81-3 (lactate) 1946833-85-7 (citrate) 1946833-89-1 (tosylate) 1946833-97-1 (tartarte) 1946833-77-7 (HCl) 1946833-97-1 （fumarate) 1946833-91-5 (mesylate)

纯度：≥98%

CAS：1403859-14-2